This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The principle (intention to treat or treatment completers only) used in the analysis of effectiveness was not explicitly specified. The primary outcome measure of the study was success rate. Success was defined as a patient either not developing acute upper-GI bleeding while receiving therapy with iv cimetidine or famotidine for stress ulcer prevention, or not having adverse reactions to cimetidine or famotidine requiring the discontinuation of the primary agent or the addition of alternative therapies. Treatment failure was defined as a patient requiring alternative or additional medications because of ineffective cimetidine or famotidine therapy, or having intolerable adverse effects and requiring alternative therapy. No comparisons were made of the baseline characteristics of the two study groups.
Effectiveness results
The probability of success for the cimetidine group was 90% (39 of 43 patients) and 89% (17 of 19) for the famotidine group.
Clinical conclusions
Efficacy was equal between cimetidine and famotidine.
Modelling
A decision tree was used to estimate the costs and effects associated with each treatment modality. Multi-attribute utility theory (MAUT) was used to incorporate a humanistic evaluation of the treatments (i.e. the tool took into account the number of doses administered per day and the number of times dosages changed during the course of therapy as the convenience factors) in addition to the economic and clinical evaluations.
Measure of benefits used in the economic analysis
As the efficacy was equal between the two treatment modalities, the decision analysis was reduced to a costminimisation study. However, MAUT was used to incorporate a humanistic evaluation of the treatments in addition to the economic and clinical evaluations.
Direct costs
Costs were not discounted due to the short time frame of the cost analysis. Resource use quantities were not reported separately from the costs and cost items were not reported separately. The cost analysis covered the costs of adverse reactions, monitoring for potential drug interactions, treatment of therapeutic failure, the addition of other medications, and a complete change in therapy. The perspective adopted in the cost analysis was that of the pharmacy and therapeutic committee. The price year appears to have been 1997.
Indirect Costs
Indirect costs were not considered.
Currency

US dollars ($).
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Estimated benefits used in the economic analysis
The convenience factors used in the MAUT analysis were as follows:
number of doses per day: 1.87 (cimetidine) versus 1.4 (famotidine); dosages were changed on average: 1.32 times (cimetidine) and 0.84 times (famotidine).
Cost results
The decision tree revealed that the average cost of receiving cimetidine for stress ulcer prophylaxis in this study was $82.01 and the average cost of famotidine therapy was $92.45.
Synthesis of costs and benefits
MAUT was used to incorporate a humanistic evaluation of the treatments in addition to the economic and clinical evaluations. The authors arbitrarily decided that efficacy would contribute 60% to the final decision, cost would contribute 20%, and the number of doses and number of dosage changes would each contribute 10%. To determine the most favourable alternative, the agent with the highest total was selected. It was found that by incorporating convenience factors at a weight of 20% in the MAUT analysis, famotidine had a slightly higher value than cimetidine (512 versus 488) and appeared to be the preferred agent. In the decision analysis, sensitivity analysis showed that as long as cimetidine is 80% effective and famotidine is equal to or less effective than cimetidine, cimetidine is the more cost-effective agent. In the MAUT analysis, it was shown that cimetidine was the preferred agent as long as cost was weighted at greater than 60% of the decision-making process and drug efficacy remained equal.
Authors' conclusions
The decision analysis showed that as long as cimetidine is 80% effective and famotidine is equal to or less effective than cimetidine, cimetidine is the more cost-effective agent. When MAUT analysis was performed famotidine was the preferred agent.
CRD COMMENTARY -Selection of comparators
No explicit justification was provided for the choice of the comparator. You, as a database user, should consider whether this is a widely used health technology in your own setting.
Validity of estimate of measure of effectiveness
The internal validity of the effectiveness results cannot be assured given the observational nature of the study design, which is prone to biases. The sample size in the study was not justified and may not have been sufficiently powered. Furthermore, it was not explicitly specified whether the effectiveness analysis was based on intention to treat or on treatment completers only and no comparisons regarding the baseline characteristics were made between the two study groups. It would have been helpful if findings from previous studies had been provided for comparison with the inputs to the decision tree.
Validity of estimate of measure of benefit
In the decision analysis, the analysis of benefit was based upon therapeutic equivalence of treatment alternatives and the economic analysis therefore included only costs. In the MAUT analysis, the estimate of benefit measures (the convenience factors) was directly obtained from the effectiveness analysis. Its use was justified based on the need to incorporate the humanistic evaluation in the analysis.
